Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: NR2B NMDA receptor antagonists - Evotec AG

Drug Profile

Research programme: NR2B NMDA receptor antagonists - Evotec AG

Alternative Names: ENS 102; EVT 100 series; EVT 102; NR2B-selective NMDA receptor antagonists; RO-631908

Latest Information Update: 03 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Evotec AG
  • Class Phenols; Piperidines; Small molecules
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Neuropathic pain; Postoperative pain

Most Recent Events

  • 01 Aug 2016 Janssen Pharmaceuticals terminates its licence for NR2B selective NMDA antagonist
  • 31 Dec 2011 Discontinued - Preclinical for Alzheimer's disease in Germany (PO)
  • 31 Dec 2011 Discontinued - Preclinical for Neuropathic pain in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top